May. 7 at 11:52 AM
$CRDL Huge exposure boost for CardiolRx getting accepted into the Journal of the American Heart Association (JAHA).
JAHA is a respected cardiovascular journal read across the industry by cardiologists, Mayo Clinic/Cleveland Clinic researchers, academic hospitals, and pharma/biotech companies like Eli Lilly, Pfizer, Novartis and AstraZeneca.
For a microcap biotech, peer-reviewed publication is important because it means the data was independently reviewed and considered clinically relevant.
And the Phase II results were strong:
• rapid pain reduction
• CRP/inflammation reduction
• major drop in recurrence rates
• favorable safety/tolerability
Combined with ARCHER showing trends toward normalization of LV mass, ECV and ICV, the scientific foundation keeps strengthening.
This is exactly the kind of exposure and validation that can put a small biotech on the radar. DYOR.
